Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies.

ABSTRACT:

Aims

A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat PK.

Methods

Data were pooled from 6 clinical studies consisting of 335 patients with solid tumours or haematological malignancies administered pevonedistat alone or in combination with azacitidine, docetaxel, carboplatin + paclitaxel, or gemcitabine. Model development and covariate analysis followed standard methods. Parameters and bootstrap 95% confidence intervals were estimated using nonlinear mixed-effects modelling. The final model was evaluated using visual predictive checks and other goodness-of-fit criteria.

Results

A linear 2-compartment model best described pevonedistat PK. The final model included the eff

SUBMITTER: Faessel HM 

PROVIDER: S-EPMC6848912 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature